Susmed (TSE:4263) Beneish M-Score: -1.59 (As of Jul. 06, 2026)


TSE:4263 Susmed Inc TSE:4263
69 GF Score
Price 円841.00
GF Value 円974.33
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Susmed Beneish M-Score?

Susmed TSE:4263 -0.36% 69 Beneish M-Score is -1.59 as of Jul. 06, 2026. GuruFocus rates TSE:4263 with a GF Score™ of 69/100 and a GF Value™ of 円974.33 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 630 Healthcare Providers & Services companies, Susmed ranks worse than 86.98% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.59 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Susmed's Beneish M-Score or its related term are showing as below:

TSE:4263' s Beneish M-Score Range Over the Past 10 Years
Min: -2.41   Med: -1.93   Max: 330.41
Current: -1.59

During the past 6 years, the highest Beneish M-Score of Susmed was 330.41. The lowest was -2.41. And the median was -1.93.


Susmed Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Susmed's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Susmed Beneish M-Score Chart

Susmed Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beneish M-Score
Get a 7-Day Free Trial 0.00 330.41 -2.41 -2.27 -1.59

Susmed Quarterly Data
Jun20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -1.59 0.00 0.00

TSE:4263 vs VEEV, BTSG, TEM: Beneish M-Score Comparison

For the Health Information Services subindustry, Susmed's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Susmed Beneish M-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Susmed's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Susmed's Beneish M-Score falls into.


TSE:4263
69GF Score
Susmed Inc TSE:4263
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Susmed Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Susmed for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0986+0.528 * 0.992+0.404 * 1.3123+0.892 * 1.3515+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7793+4.679 * 0.029774-0.327 * 0.4292
=-1.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun25) TTM:Last Year (Jun24) TTM:
Total Receivables was 円15.4 Mil.
Revenue was 円463.0 Mil.
Gross Profit was 円450.7 Mil.
Total Current Assets was 円4,462.6 Mil.
Total Assets was 円4,503.0 Mil.
Property, Plant and Equipment(Net PPE) was 円0.0 Mil.
Depreciation, Depletion and Amortization(DDA) was 円8.0 Mil.
Selling, General, & Admin. Expense(SGA) was 円476.6 Mil.
Total Current Liabilities was 円125.9 Mil.
Long-Term Debt & Capital Lease Obligation was 円0.0 Mil.
Net Income was 円-298.4 Mil.
Gross Profit was 円0.0 Mil.
Cash Flow from Operations was 円-432.5 Mil.
Total Receivables was 円10.4 Mil.
Revenue was 円342.6 Mil.
Gross Profit was 円330.9 Mil.
Total Current Assets was 円4,898.4 Mil.
Total Assets was 円4,932.1 Mil.
Property, Plant and Equipment(Net PPE) was 円0.0 Mil.
Depreciation, Depletion and Amortization(DDA) was 円6.0 Mil.
Selling, General, & Admin. Expense(SGA) was 円452.5 Mil.
Total Current Liabilities was 円321.4 Mil.
Long-Term Debt & Capital Lease Obligation was 円0.0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(15.404 / 462.988) / (10.375 / 342.577)
=0.033271 / 0.030285
=1.0986

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(330.85 / 342.577) / (450.724 / 462.988)
=0.965768 / 0.973511
=0.992

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (4462.629 + 0) / 4502.972) / (1 - (4898.414 + 0) / 4932.086)
=0.008959 / 0.006827
=1.3123

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=462.988 / 342.577
=1.3515

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(5.987 / (5.987 + 0)) / (7.975 / (7.975 + 0))
=1 / 1
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(476.569 / 462.988) / (452.478 / 342.577)
=1.029333 / 1.320807
=0.7793

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 125.94) / 4502.972) / ((0 + 321.399) / 4932.086)
=0.027968 / 0.065165
=0.4292

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-298.404 - 0 - -432.477) / 4502.972
=0.029774

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Susmed has a M-score of -1.59 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.59 mean?
Susmed (TSE:4263) has a Beneish M-Score of -1.59 as of Jul. 06, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Susmed and its competitors. According to the industry distribution chart, Susmed ranks #548 out of 630 companies in the Healthcare Providers & Services industry, placing it in the top 87%.
Is Susmed's Beneish M-Score too high?
Susmed's current Beneish M-Score is -1.59. Based on the distribution chart, Susmed ranks #548 out of 630 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Susmed has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Susmed's Beneish M-Score compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Susmed ranks #548 out of 630 companies for Beneish M-Score. This places Susmed in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Healthcare Providers & Services company?
A good Beneish M-Score depends on the Healthcare Providers & Services industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Susmed and its competitors. Susmed's current Beneish M-Score is -1.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Susmed stock overvalued right now?
Based on GuruFocus' analysis, Susmed (TSE:4263) is currently considered Modestly Undervalued. The stock's GF Value™ is 円974.33, compared to a current price of 円841.00 — trading 13.7% below its estimated fair value. The current Beneish M-Score is -1.59. Susmed's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Susmed (TSE:4263), the current Beneish M-Score is -1.59 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Susmed (TSE:4263) Overvalued in 2026?

Based on GuruFocus' analysis, Susmed stock appears to be undervalued. The current stock price of 円841.00 is trading 13.7% below its estimated GF Value™ of 円974.33. GuruFocus considers Susmed to be Modestly Undervalued.

Key valuation signals for TSE:4263:

  • Beneish M-Score: -1.59
  • GF Value™: 円974.33 vs. price of 円841.00 (13.7% below fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the TSE:4263 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Susmed Business Description

Address 3-7-2 Nihonbashi Honcho, 10th Floor, MFPR Nihonbashi Honcho Building, Chuo-ku, Tokyo, JPN, 103-0023
Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.
69GF Score

Get the complete analysis for TSE:4263

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円841.00
Price
円974.33
GF Value